ES2092316T3 - Agentes antianginosos de purinona. - Google Patents

Agentes antianginosos de purinona.

Info

Publication number
ES2092316T3
ES2092316T3 ES93914675T ES93914675T ES2092316T3 ES 2092316 T3 ES2092316 T3 ES 2092316T3 ES 93914675 T ES93914675 T ES 93914675T ES 93914675 T ES93914675 T ES 93914675T ES 2092316 T3 ES2092316 T3 ES 2092316T3
Authority
ES
Spain
Prior art keywords
alkyl
purinona
angulous
agents
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93914675T
Other languages
English (en)
Inventor
Nicholas Kenneth Terrett
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Research and Development Co NV SA
Original Assignee
Pfizer Research and Development Co NV SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Research and Development Co NV SA filed Critical Pfizer Research and Development Co NV SA
Application granted granted Critical
Publication of ES2092316T3 publication Critical patent/ES2092316T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/28—Oxygen atom
    • C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Photoreceptors In Electrophotography (AREA)
  • Catalysts (AREA)
  • Signal Processing For Digital Recording And Reproducing (AREA)
  • Paper (AREA)
  • Production Of Liquid Hydrocarbon Mixture For Refining Petroleum (AREA)
  • Vending Machines For Individual Products (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

SE PRESENTAN COMPUESTOS DE LA FORMULA (I) Y LAS SALES FARMACOLOGICAMENTE ACEPTABLES DE LOS MISMOS, EN DONDE R1 ES ALQUILO C1-C4; R2 ES ALQUILO C2-C4; R3 ES H O SO2NR4R5; R4 Y R5 JUNTO CON EL ATOMO DE NITROGENO AL CUAL ESTAN UNIDAS FORMAN UN GRUPO DE PIRROLIDINO, PIPERIDINO, MORFOLINO O 4-N-(R6)-1-PIPERAZINIL; Y R6 ES H O ALQUILO C1-C3; LOS COMPUESTOS SON INHIBIDORES SELECTIVOS DEL CGMP PDE UTILES EN EL TRATAMIENTO DE ENFERMEDADES CARDIOVASCULARES TALES COMO LA ANGINA, LA HIPERTENSION, EL FALLO CARDIACO Y LA ARTERIOSCLEROSIS.
ES93914675T 1992-06-26 1993-06-18 Agentes antianginosos de purinona. Expired - Lifetime ES2092316T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB929213623A GB9213623D0 (en) 1992-06-26 1992-06-26 Therapeutic agents

Publications (1)

Publication Number Publication Date
ES2092316T3 true ES2092316T3 (es) 1996-11-16

Family

ID=10717795

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93914675T Expired - Lifetime ES2092316T3 (es) 1992-06-26 1993-06-18 Agentes antianginosos de purinona.

Country Status (11)

Country Link
EP (1) EP0647227B1 (es)
JP (1) JP2544903B2 (es)
AT (1) ATE143961T1 (es)
CA (1) CA2139109C (es)
DE (1) DE69305344T2 (es)
DK (1) DK0647227T3 (es)
ES (1) ES2092316T3 (es)
FI (1) FI946083L (es)
GB (1) GB9213623D0 (es)
GR (1) GR3021878T3 (es)
WO (1) WO1994000453A1 (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI951367A7 (fi) * 1994-03-28 1995-09-29 Japan Energy Corp Puriinijohdannaiset ja tulehdustautien tukahduttajat (suppressantit)
GB9423911D0 (en) * 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents
GB9423910D0 (en) 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents
DE19501482A1 (de) * 1995-01-19 1996-07-25 Bayer Ag 2,9-disubstituierte Purin-6-one
DE19501480A1 (de) * 1995-01-19 1996-07-25 Bayer Ag 9-substituierte 2-(2-n-Alkoxyphenyl)-purin-6-one
US5656629A (en) * 1995-03-10 1997-08-12 Sanofi Winthrop, Inc. 6-substituted pyrazolo (3,4-d)pyrimidin-4-ones and compositions and methods of use thereof
JPH1087666A (ja) * 1996-09-18 1998-04-07 Kyorin Pharmaceut Co Ltd デュオカルマイシンｓａ及びその誘導体の製造中間体と製造方法
DE19702785A1 (de) * 1997-01-27 1998-07-30 Bayer Ag Neue cyclische Harnstoffderivate
CA2288910C (en) 1997-04-25 2003-06-24 Pfizer Inc. Pyrazolopyrimidinones for sexual dysfunction
GB9722520D0 (en) 1997-10-24 1997-12-24 Pfizer Ltd Compounds
HU227841B1 (en) 1997-11-12 2012-05-02 Bayer Pharma AG 2-phenyl substituted imidazotriazinones, process for their preparation and pharmaceutical compositions thereof
ES2203078T3 (es) 1998-04-20 2004-04-01 Pfizer Inc. Parazolopirimidinonas inhibidoras de gmpc pde5 para el tratamiento de la disfuncion sexual.
WO1999062905A1 (en) * 1998-06-03 1999-12-09 Almirall Prodesfarma, S.A. 8-phenylxanthine derivatives and their use as phosphodiesterase inhibitors
US6087368A (en) * 1998-06-08 2000-07-11 Bristol-Myers Squibb Company Quinazolinone inhibitors of cGMP phosphodiesterase
DE19838300A1 (de) * 1998-08-24 2000-03-02 Bayer Ag 9-Dialkylaminopurinon-derivate
US6326379B1 (en) * 1998-09-16 2001-12-04 Bristol-Myers Squibb Co. Fused pyridine inhibitors of cGMP phosphodiesterase
GB9823101D0 (en) 1998-10-23 1998-12-16 Pfizer Ltd Pharmaceutically active compounds
GB9823103D0 (en) 1998-10-23 1998-12-16 Pfizer Ltd Pharmaceutically active compounds
GB9823102D0 (en) 1998-10-23 1998-12-16 Pfizer Ltd Pharmaceutically active compounds
US6225315B1 (en) 1998-11-30 2001-05-01 Pfizer Inc Method of treating nitrate-induced tolerance
TWI265925B (en) 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them
GB9924020D0 (en) * 1999-10-11 1999-12-15 Pfizer Ltd Pharmaceutically active compounds
HK1049834A1 (zh) 1999-10-11 2003-05-30 辉瑞大药厂 用作磷酸二酯酶抑制剂的5-(2-取代的-5-杂环基磺酰基吡啶-3-基)-二氢吡唑并[4，3-d]嘧啶-7-酮类化合物
JP2003519151A (ja) * 1999-12-24 2003-06-17 バイエル アクチェンゲゼルシャフト トリアゾロトリアジノンおよびそれらの使用
CN1630532A (zh) * 2000-04-19 2005-06-22 约翰斯霍普金斯大学 预防和治疗胃肠疾病的方法
US6548508B2 (en) 2000-10-20 2003-04-15 Pfizer, Inc. Use of PDE V inhibitors for improved fecundity in mammals
AU2002358772B2 (en) 2001-12-20 2008-11-20 Merck Serono Sa Pyrrolidine derivatives as prostaglandin modulators
GB0202282D0 (en) 2002-01-31 2002-03-20 Pfizer Ltd Treatment of male sexual dysfunction
DE10232113A1 (de) 2002-07-16 2004-01-29 Bayer Ag Vardenafil Hydrochlorid Trihydrat enthaltende Arzneimittel
GB0219961D0 (en) 2002-08-28 2002-10-02 Pfizer Ltd Oxytocin inhibitors
US7323462B2 (en) 2002-12-10 2008-01-29 Pfizer Inc. Morpholine dopamine agonists
PT1572173E (pt) 2002-12-13 2010-05-10 Warner Lambert Co Ligando alfa-2-delta para tratar sintomas do tracto urinário inferior
KR100824193B1 (ko) 2003-04-29 2008-04-21 화이자 인코포레이티드 고혈압 치료에 유용한5,7-디아미노피라졸로[4,3-ｄ]피리미딘
US7291640B2 (en) 2003-09-22 2007-11-06 Pfizer Inc. Substituted triazole derivatives as oxytocin antagonists
US7572799B2 (en) 2003-11-24 2009-08-11 Pfizer Inc Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
JP2007532526A (ja) 2004-04-07 2007-11-15 ファイザー・インク ピラゾロ［４，３−ｄ］ピリミジン類
JP2008533192A (ja) 2005-03-21 2008-08-21 ファイザー・リミテッド オキシトシンアンタゴニストとしての置換されたトリアゾール誘導体
PT1881985E (pt) 2005-05-12 2011-02-01 Pfizer Formas cristalinas anidras de n-[1-(2-etoxietil)-5-(n- -etil-n-metilamino)-7-(4-metilpiridin-2-il-amino)-1h- -pirazolo[4,3-d]pirimidino-3-carbonil]metanossulfonamida
US9402877B2 (en) 2011-11-04 2016-08-02 Xion Pharmaceuticals Corporation Methods and compositions for oral administration of melanocortin receptor agonist compounds

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1338235A (en) * 1970-12-15 1973-11-21 May & Baker Ltd Azapurinones
CA1303037C (en) * 1987-02-02 1992-06-09 Smith Kline & French Laboratories Limited Purinone derivatives as bronchodilators vasodilators and anti-allergic agents
ES2058527T3 (es) * 1988-06-16 1994-11-01 Smith Kline French Lab Derivados de pirimidina condensados procedimiento y compuestos intermedios para su preparacion y composiciones farmaceuticas que los contienen.
GB8817651D0 (en) * 1988-07-25 1988-09-01 Smith Kline French Lab Chemical compounds

Also Published As

Publication number Publication date
DE69305344D1 (de) 1996-11-14
WO1994000453A1 (en) 1994-01-06
EP0647227A1 (en) 1995-04-12
CA2139109A1 (en) 1994-01-06
JP2544903B2 (ja) 1996-10-16
FI946083A7 (fi) 1994-12-23
GB9213623D0 (en) 1992-08-12
CA2139109C (en) 1997-03-25
EP0647227B1 (en) 1996-10-09
FI946083A0 (fi) 1994-12-23
ATE143961T1 (de) 1996-10-15
JPH07504681A (ja) 1995-05-25
DK0647227T3 (da) 1996-11-18
FI946083L (fi) 1994-12-23
DE69305344T2 (de) 1997-02-20
GR3021878T3 (en) 1997-03-31

Similar Documents

Publication Publication Date Title
ES2114952T3 (es) Agentes antianginales derivados de quinazolinona.
ES2071919T3 (es) Agentes antianginosos de pirazolopirimidina.
ECSP045368A (es) "antagonistas de los receptores de trombina"
ES2096936T3 (es) Agentes antianginales de piridopirimidinona.
CO5680403A2 (es) Antagonistas de mchr1r
AR025976A1 (es) Inhibidores de fab i.
ES2183905T3 (es) Inhibidores de metaloproteasa de matriz.
EA200400550A1 (ru) Бициклические производные оксопиридина и оксопиримидина
CO5601002A2 (es) Inhibidores de la acc
AR046711A1 (es) 5-7-diaminopirazolo[4,3d]pirimidinas como inhibidores de la pde-5,composiciones farmaceuticas que las contienen y usos en el tratamiento de hipertensiones
ECSP034475A (es) Derivados de 4-fenil-piridin como antagonistas del receptor de neuroquinina-1
MX9300031A (es) Derivados de piperazina, procedimiento para su preparacion y composicion farmaucetica que los contiene.
AR037907A1 (es) Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6
DK0647227T3 (da) Purinon antianginamidler
CO5570668A2 (es) Derivados triciclicos sustituidos de himbacina que son antagonistas del receptor de trombina y composiciones farmaceuticas que los contienen
ES2107506T3 (es) Pirazolopirimidonas como agentes antianginosos.
AR040566A1 (es) Derivados de 1-heterociclilalquil 3- sulfonilazaindol o azaindazol como ligandos de 5 hidroxitriptamina-6
AR044543A1 (es) Derivados de pirazolo-quinazolina, un procedimiento para su preparacion y su uso como inhibidor de quinasa
AR087046A2 (es) Compuestos derivados de 4-oxoquinolina
ES2143526T3 (es) Derivados de amida que tienen actividad antihipercolesterolemica, su preparacion y sus usos terapeuticos.
AR037906A1 (es) Derivados de indolilalquilamina como ligandos de 5-hidroxitriptamina-6
ES476535A1 (es) Un procedimiento para la preparacion de nuevos derivados de acidos pirrol-1-carboxilicos.
EA200000400A1 (ru) Галогензамещенные тетрациклические производные тетрагидрофурана
ES2136291T3 (es) Derivados de pirimidina.
EA200100710A1 (ru) 4-(аминометил)пиперидинбензамиды для лечения желудочно-кишечных расстройств

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 647227

Country of ref document: ES